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Abstract Interleukin-1 (IL-1), a proinflammatory cytokine
synthesized and released by activated microglia, can cause
dopaminergic neurodegeneration leading to Parkinson’s dis-
ease (PD). However, it is uncertain whether IL-1 can act di-
rectly, or by exacerbating the harmful actions of other brain
insults. To ascertain the role of the IL-1 pathway on dopami-
nergic neurodegeneration and motor skills during aging, we
compared mice with impaired [caspase-1 knockout (casp1−/
−)] or overactivated IL-1 activity [IL-1 receptor antagonist
knockout (IL-1ra−/−)] to wild-type (wt) mice at young and
middle age. Their motor skills were evaluated by the open-
field and rotarod tests, and quantification of their dopamine
neurons and activated microglia within the substantia nigra
were performed by immunohistochemistry. IL-1ra−/− mice
showed an age-related decline in motor skills, a reduced num-
ber of dopamine neurons, and an increase in activated microg-
lia when compared to wt or casp1−/−mice. Casp1−/−mice had
similar changes in motor skills and dopamine neurons, but
fewer activated microglia cells than wt mice. Our results sug-
gest that the overactivated IL-1 pathway occurring in IL-1ra−/−
mice in the absence of inflammatory interventions (e.g., intra-
cerebral injections performed in animal models of PD) in-
creased activated microglia, decreased the number of dopami-
nergic neurons, and reduced their motor skills. Decreased IL-1
activity in casp1−/− mice did not yield clear protective effects
when compared with wt mice. In summary, in the absence of
overt brain insults, chronic activation of the IL-1 pathwaymay
promote pathological aspects of PD per se, but its impairment
does not appear to yield advantages over wt mice.
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Introduction
A growing body of evidence suggests that inflammatory me-
diators play a pivotal role in aging and neurodegenerative
disorders such as Parkinson’s disease (PD), a condition that
affect more than 1% of the population aged 60 years and older
in industrialized countries [1]. A hallmark for the pathophys-
iology of PD is dopaminergic neurodegeneration within the
substantia nigra (SN) pars compacta (SNpc), which leads to
decreased striatal dopamine (DA) levels and affects the con-
trol of voluntary movements [2]. Activation of microglia, ei-
ther by age or different insults, has been proposed as a key
neuroinflammatory process leading to the progression of do-
paminergic neurodegeneration [3]. Activated microglia re-
lease a number of inflammatory factors, which in turn trigger
a neuroinflammatory cascade causing neuronal damage [4, 5].
Interleukin-1 (IL-1) is one of the most well-known proin-
flammatory cytokines that act within the brain during different
insults and neurodegenerative diseases, including PD [6]. The
IL-1 system involves two essential agonists, IL-1 alpha (IL-
1α) and IL-1 beta (IL-1β), as well as the endogenous antag-
onist, IL-1 receptor antagonist (IL-1ra) [7]. Both IL-1α/β ex-
ert similar biological effects by binding to IL-1 receptor 1 (IL-
1R1), whereas IL-1ra blocks IL-1α/β biological activity by
competing with them by binding to IL-1R1 [7, 8]. Upon bind-
ing to IL-1R1, IL-1ra does not trigger any second messenger
signal [7, 8]. Another key component of the IL-1 system is
caspase-1 (casp1), a cysteine protease that, when cleaved, ac-
tivates the immature form of IL-1. The activation of casp1
controls the rate-limiting step in the conversion of pro-IL-
1beta into the mature biologically active cytokine. Thus, IL-
1ra and casp1 are two key targets that modulate the IL-1
system.
The crucial roles of impairing or activating the IL-1 path-
way have been evidenced by the diametrically opposed re-
sponse that caspase-1 knockout (casp1−/−) and interleukin-1
receptor antagonist knockout (IL-1ra−/−) mice, respectively,
display after being challenged with high doses of lipopolysac-
charide from Gram-negative bacteria (LPS) [9, 10]. In fact,
casp1−/− mice are largely resilient [9], whereas IL-1ra−/− mice
are much more susceptible to death after receiving high doses
of LPS [10].Within the central nervous system (CNS), casp1−/
−mice display a lower inflammatory response after receiving a
systemic challenge with LPS when compared to wild-type
(wt) mice [11, 12]. In contrast, IL-1ra−/− mice display an en-
hanced CNS inflammatory response and are more sensitive to
a central inflammatory challenge [13]. Moreover, the latter
study showed that activated microglia play an essential role
in the neuroinflammatory cascade [13].
Within the brain, IL-1 is mainly synthesized and released
by activated microglia [14]. Several lines of research, includ-
ing preclinical [15–17] and post-mortem studies [18], have
suggested that IL-1 pathway activation is involved in mecha-
nisms causing neurotoxicity [15–18]. It is not completely un-
derstood whether the activation of IL-1 causes neurotoxicity
per se or if its involvement in dopaminergic neurodegenera-
tion requires preexistent triggering insults. There is evidence
contradicting the direct role of IL-1β on neuronal death [19,
20], but supporting its role in exacerbating brain damage
caused by other triggering factors such as traumatic, ischemic,
or excitotoxic stimuli [20].
In order to better understand the role of the IL-1 pathway in
neurotoxicity and in the dysregulation of the nigrostriatal sys-
tem during aging, we employed a noninvasive approach to
study locomotion and motor coordination activity in young
adult mice with impaired (casp1−/−) or overactive (IL-1ra−/−)
IL-1 pathway. We tested the hypothesis that these strains dis-
play differential locomotion and body balance regulation dur-
ing aging. At the end of the study, we also estimated the
number of dopaminergic neurons and activated microglia
within the SN.
Materials and Methods
All animal experiments were performed according to the rules
and regulations of the BAustralian code of practice for the care
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and use of animals for scientific purposes.^ All experimental
protocols were approved by the Australian National
University Animal Experimentation Ethics Committee
(AEEC).
Animals
Groups of wt, casp1−/− [9], and IL-1ra−/− [10] mice, bred in
C57BL/6 background, were evaluated. All mice (10–12 per
group) were fed a regular chow diet (food and water ad
libitum), housed in groups of up to five animals per cage
and maintained under standard living conditions (22 ± 2 °C,
12-/12-h light/dark cycle) for the entire duration of the studies.
Behavioral Tests
Locomotion, coordination, and balance skills were evaluated
when mice were young (42–45 days old), and 9 months later
(i.e., when they became over 10 months old). This period was
selected based on a previous study that showed that immuno-
logical challenged mice with monthly intraperitoneal (i.p.)
injections of LPS showed impaired motor skills after 9 months
of receiving the first injection [21]. Locomotion was deter-
mined by placing each individual mouse in an open-field are-
na (48 cm × 48 cm), and recording its activity for 32 min with
a video camera placed from the top of the arena. The software
BViewer 3^ (Biobserve Gmbh, St. Augustin, Germany) was
used for data collection and processing, which provided mea-
sures of the total distance travelled.
Coordination and balance skills were ascertained by
employing a rotarod apparatus (Panlab, Harvard apparatus,
Barcelona, Spain). Prior to starting data collection, mice were
trained for 4–6 days and were given three trials per day in
order to achieve maximal performance in the rotarod test
[22–24]. All of the mice were included since they were suc-
cessfully trained for this behavioral paradigm, and they looked
healthy throughout the entire duration of the study as per rou-
tine inspections of their fur, body weight, response to han-
dling, and home cage social behavior. The mice were fre-
quently monitored by the researchers and technical staff of
the Australian National University animal facility. Upon plac-
ing the mice on the rotating drum, the initial speed was 4
revolutions per minute (rpm), and it was accelerated to
40 rpm within 2 min. Mice were given three trials with 2-
min breaks between trials. The latency to fall from the rotating
drum was measured in seconds. Mice that showed better bal-
ance and coordination skills were able to remain for a longer
period of time on the rotating drum. The final result was cal-
culated as the mean of the latency to fall from the rotarod
apparatus during the three trials. In the infrequently observed
event in which the mouse had not fallen from the rotating
drum after 2 min, it was removed from the apparatus and
returned to its home cage [21]. Behavioral assessments in
the rotarod and open-field tests are frequently used to deter-
mine parkinsonism-related outcomes [25–28].
Henceforth, the first behavioral assessments obtained at
young age (42–45 days old) will be referred as Bbaseline,^
and those obtained 9 months later as B9 months.^ Thus, for
simplicity purpose, baseline is considered as the Bzero point^
and any other mentioned experimental time-point will reflect
the time elapsed from baseline unless otherwise stated.
Immunohistochemistry of Dopamine Neurons
and Microglia Cells
Tissue Preparation
Fifteen months after the initiation of the experiments, mice
were anesthetized with an intraperitoneal injection of
ketamine/xylazine (100/10 mg/kg, adjusted to a volume of
0.1 ml/10 g of body weight) and transcardially perfused with
a solution of cold phosphate-buffered saline (PBS) and hepa-
rin (5 U/ml) within 3 min. The mouse brain was removed and
frozen in chilled isopentanol and stored at −80 °C until use.
Brains were sliced using a cryostat (set at −12 °C) in 15-μm
coronal sections throughout the entire SN.
Immunohistochemistry
We followed previously reported protocols for tyrosine hy-
droxylase (TH) and microglia staining with minor modifica-
tions [29, 30]. Brain sections were collected on gelatin-coated
slides, air-dried and post-fixed in 4 % paraformaldehyde
(pH∼7.4 in PBS) for 8–10 min. After a PBS wash (three times
within 5 min), sections were incubated for 20 min in 3 %
peroxide mixed in methanol in order to inactivate the endog-
enous peroxidase. Sections were incubated with 5 % normal
goat serum and 0.015 % Triton X-100 in PBS. After 30 min of
incubation, the sections were incubated with rabbit anti-TH
antibody (1:1000 dilution; Life Technology, cat# P21962)
[29], or rat anti-mouse CD68 monoclonal antibody (1:700;
AbD Serotec, cat# MCA341GA) in 0.015 % Triton X-100
for 24 h at 4 °C [30]. On the following day, the slides were
washed in PBS and incubated with biotinylated goat anti-
rabbit (1:200; Vector Laboratories, cat# PK-6101) or goat
anti-rat secondary antibody (1:500; Vector Laboratories, cat#
BA-9400) for 1 h. After a PBS wash, slides were reacted with
avidin-biotin complex (ABC; Vector Laboratories, cat# PK-
6101) for 30 min. In the final step, slides were washed with
PBS and incubated with 3,3′-diaminobenzidine (DAB; Sigma,
cat# D3939) and 30 % peroxide until color development (5–
7 min). Slides were counterstained with hematoxylin (30 s),
dehydrated in alcohol gradient (80, 90, 100, 100 %), im-
mersed in xylene, mounted with DPX slide mounting medium
(Sigma, cat# 05622), and coverslipped. All the incubations
were done at room temperature, unless mentioned otherwise.
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Quantification of Dopamine Neurons and Microglia
In order to assess the loss of dopamine neurons and the num-
ber of activated of microglia cells, two adjacent series of eight
consecutive slides (15 μm of thickness) were collected to
sample the region of SN (rostral to caudal: −2.65 to
−3.61 mm posterior to bregma) [21]. Thus, the two series of
eight evenly spaced slides were obtained every 90 μm and
were used for counting dopamine neurons or activated mi-
croglia cells. The borders of SN were defined in order to
exclude the ventral tegmental area (VTA) from counting
[31]. The area defined for counting covered the entire area
from the rostral part of SNpc to the caudal end of SN pars
reticulata (SNpr), excluding those TH neurons that inter-
spersed with oculomotor nerve rootlet. Images were obtained
with an IX2-UCB Olympus digital camera (Olympus, Tokyo,
Japan) and analyzed manually using the ImageJ software
(http://imagej.nih.gov from NIH). Positive CD68 microglia
cells in SN were counted manually on a Nikon Eclipse 50i
microscope (Nikon, Tokyo, Japan) . The pic ture
magnifications were ×20 and ×40 for microglia and ×20 for
TH.
Statistical Analysis
Data were analyzed with GraphPad software version 5
(GraphPad Software, La Jolla California USA) and expressed
as mean ± standard error of the mean (S.E.M). One-way
ANOVA followed by Newman-Keuls post hoc test was used
to analyze the differences among the three genotypes (wt,
casp1−/−, and IL-1ra−/−). Values of P < 0.05 were considered
significant.
Results
Age-Related Decline of Motor Skills in IL-1ra−/− Mice
In order to better understand the role of IL-1 signaling
on dysregulation of the nigrostriatal system, the open-
field and the rotarod tests were performed to assess
locomotion and coordination/balance in all groups of
mice. We evaluated their performance at young age
(baseline) and at 9 months later (i.e., when they became
nearly/or 10.5 months old). Figure 1a–c displays the
percentage of change in total distance travelled in the
open-field arena between baseline and 9 months by
mice of the three genotypes. Results were expressed as
percentage change relative to baseline measurements,
which was considered to be 100 %. This was calculated
as follows: total distance at 9 months / total distance
traveled at baseline × 100 %. IL-1ra−/− mice showed a
significant 53 % decline in locomotor activity (P <
0.0001), whereas wt and casp1−/− displayed similar ac-
tivity at both time-points (Fig. 1a–c). Figure 1d shows
the comparison of change of distance traveled from
baseline and 9 months later between the three geno-
types. At 9 months, the locomotor activity was reduced
by 53 % in IL-1ra−/− mice when compared to baseline,
and this decline was significantly different from the
changes observed in wt (P < 0.001) and casp1−/− mice
(P < 0.01) (Fig. 1d).
The rotarod apparatus is largely used to test coordination
and balance skills in rodents where the latency to fall from the
rotating drum is recorded and used as a measure of their motor
coordination and balance abilities [32, 33]. Figure 2a–c dis-
plays the change between baseline and 9 months later in the
average elapsed time to fall down from the rotating drum of
the rotarod apparatus for all groups of mice. The latency to fall
from the rotating drum obtained after 9 months of the first
assessments was expressed as percentage relative to baseline,
which was considered to be 100 % (Fig. 2a–c). Significant
levels of decline in their performance of 23 % (P<0.05),
37 % (P<0.05), and 63 % (P<0.001) were observed in the
wt, casp1−/−, and IL-1ra−/− groups, respectively (Fig. 2a–c).
The genotype comparison showed that the rotarod perfor-
mance of IL-1ra−/− mice was significantly more pronounced
than the 23 % decline observed in wt (P < 0.01) and the 37 %
decline displayed by casp1−/− mice (P < 0.05) (Fig. 2d).
Role of IL-1 Signaling in Microglia Activation
and Neurodegeneration of Dopamine Neurons in SN
In order to assess the role of IL-1 on neuronal degeneration of
dopamine neurons, the total number of TH-positive neurons
was quantified from eight evenly spaced frozen sections of the
brain that encompassed the entire region of the SNpc.
Representative pictures displaying positive TH staining of do-
pamine neurons in SNpc of wt, casp1−/−, and IL-1ra−/− mice
are shown in Fig. 3 (left panels). As presented in Fig. 4, there
was a reduction of up to 24% of dopamine neurons in IL-1ra−/
− mice in comparison to wt (P < 0.05) and casp1−/− (P <
0.001) mice.
To further understand the implication of activated
microglial cells in the neurodegeneration of dopamine neu-
rons, activated microglia/macrophages were stained with the
CD68 marker and counted in the area of the SNpc and SNpr.
A positive CD68 staining of activated microglia cells in the
SN of wt, casp1−/−, and IL-1ra−/− is presented in Fig. 3 (right
panels). As presented in Fig. 5, casp1−/− mice had a signifi-
cantly lower number of activated microglia (approximately
50 %) in comparison to wt and IL-1ra−/−mice, suggesting that
these mice show an overall lower inflammation within the
brain. On the other hand, IL-1ra−/−mice had significant higher




We have ascertained the role of the IL-1 pathway on long-term
locomotion and motor coordination in wt, IL-1ra−/−, and
casp1−/− mice displaying normal, overactive, or impaired IL-
1 pathway, respectively. Our hypothesis was that, in the ab-
sence of overt brain insults, chronic activation of the IL-1
system evokes parkinsonism-related behaviors during aging,
whereas impairment of IL-1 activity in casp1−/−mice results in
neuroprotection and better performance. Our results in IL-
1ra−/− mice suggest that overactivation of microglia cells by
IL-1 decreases the number of dopaminergic neurons, which in
turn reduces locomotion and motor coordination to promote
pathological aspects of parkinsonism. However, our results
show that deficiency of casp1 does not exert a clear protection
in sparing motor skills during aging, despite the fact that these
mice display fewer activated microglia.
In our study, we tested mice in an open-field arena to assess
their voluntary locomotor activity and in an accelerating
rotarod apparatus to determine their motor coordination and
balance. These two behavioral paradigms are widely used to
evaluate parkinsonism-related behavior in rodents [25–28].
Baseline was defined as the time-point we started the experi-
ments with young adult mice (42–45 days old), whereas
9 months was the time we finalized their behavioral
assessments (i.e., mice were over 10 months old). This period
of time was selected based on previous data showing that
endotoxin-challenged mice with five monthly intraperitoneal
LPS injections displayed decreased motor skills capabilities
9 months after the first injection [21].
IL-1ra−/− mice displayed a much more pronounced de-
crease in both motor coordination and locomotor activity
when compared to wt and casp1−/− mice 9 months later. The
latter suggests that chronic exacerbation of the IL-1 pathway
affects dopaminergic neurotransmission and impairs motor
skills. This concept is supported by our histological studies
because IL-1ra−/− mice displayed an increased number of ac-
tivated microglia cells and a decreased number of dopaminer-
gic neurons compared to wt and casp1−/− mice. The patho-
physiological role of microglial-induced neuroinflammation
in PD was originally described by McGeer et al. in 1988,
when they showed the presence of activated microglia in the
SN of PD patients [18, 34]. Studies carried in other species
such as monkeys [35] and rodents [36–38] also provided
strong evidence of activated microglia in impaired dopaminer-
gic neurotransmission [35–38]. Furthermore, the prominent
role of IL-1β has been described in rats that were centrally
injectedwith adenovirus expressing IL-1β, which caused neu-
rotoxicity within hippocampus and SN [15–17, 39], and in IL-


































































Fig. 1 Total distance travelled during open-field test. a–c Comparison of
the total distance travelled by wt (n = 10), casp1−/− (n = 8) and IL-1ra−/−
(n = 12) mice between baseline and 9 months. Baseline performance was
considered as 100 %. The total distance at 9 months is expressed as
percentage of baseline. d Comparison of the average differences between
9 months and baseline for each genotype; the differences were calculated
for each mouse and expressed as percentage of baseline by using the
following formula: [(Td 9M − Td B) / Td B] × 100, where BTd 9M^ and
BTd B^ represent the total distance at 9 months and baseline, respectively.
In this and in following graphs, each column represents the mean, and the
bar above denotes the standard error of the mean (SEM). For the statis-
tical comparison between two groups (a–c), we employed paired t tests,
whereas for the comparison of three groups (d), we performed one-way
ANOVA followed by Newman-Keuls post hoc test. ***P < 0.001 vs. wt;
++P < 0.01 vs. casp−/−
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noteworthy that the chronic expression of IL-1β within the
SN in rats was sufficient to elicit microglial activation and
dopaminergic neurodegeneration [16], which were exacerbat-
ed by concomitant systemic expression of IL-1β [39]. The
data described about IL-1ra−/− mice herein are aligned with
the latter mentioned studies and support the concept that IL-1-
induced neuroinflammation could have resulted in activation
of the neuroinflammatory cascade causing a decreased num-
ber of TH neurons within the SN [15, 16, 39]. Hence, de-
creased dopaminergic cell bodies in the SN could explain
the lower capabilities in motor skills displayed by IL-1ra−/−
mice 9 months after performing the first open field and rotarod
tests.
However, there appears to be some controversy surround-
ing the putative direct neurotoxic role of IL-1 within the brain.
For instance, it has been also suggested that some of the pre-
viously provided in vivo evidence [15–17] could have been
influenced by confounding technical variables (i.e., inflamma-
tion caused by intracerebral injection, viral administration, or
nonphysiologic doses of IL-1β) [40]. Moreover, it has been
proposed that IL-1β cannot exert neurotoxicity per se within
the CNS but rather exacerbates the inflammatory cascade elic-
ited by other insults [40]. That concept is supported by mouse
studies showing that chronic overexpression of human IL-1β
for a period of 2 months within the hippocampus does not
seem to cause evident signs of overt neurodegeneration [41].
Additionally, in vitro studies also suggested that IL-1β cannot
exert neurotoxicity per se [42, 43]. Since our approach did not
require central interventions that could cause brain inflamma-
tion, it is quite likely that increased IL-1 is largely responsible
for the impairment in motor skills that IL-1ra−/− mice showed
9 months later of starting the behavioral experiments. Since
we employed a traditional constitutive knockout model that
lacks IL-1ra, our results are influenced by the combined action
of both IL-1β and IL-1α. Therefore, it is likely that some of
the seemingly differences between our data and other studies
reporting the lack of action of IL-1β in brain neurotoxicity
could be, at least partially, due to the fact that in this mouse
model, we tested the unopposed actions to both IL-1β and IL-
1α. Additionally, our findings might be affected not only by
the overactivation of the IL-1 system within the CNS but also
in the periphery, which collectively could affect dopaminergic
neurotransmission [6, 39].
As mentioned above, the putative protective impact of de-
creased activation of the IL-1 pathway was ascertained in
casp1−/− mice, since this strain lacks biologically active IL-
1β and shows much lower levels of IL-1α than wt mice [9].
Furthermore, in previous studies, we have shown that casp1−/−
displayed a lower level of brain inflammation than wt mice



































































Fig. 2 Rotarod performance. a–c Comparison of the average latency to
fall from the rotating drum displayed by wt (n = 10), casp1−/− (n = 8), and
IL-1ra−/− (n = 12) mice at baseline and 9 months. The differences were
calculated for each mouse and expressed as percentage of baseline by
using the following formula: [(L9M − LB) / LB] × 100, where BL9M^
and BLB^ represent the latency to fall at 9 months and baseline,
respectively. d Comparison of the average differences between
9 months and baseline for each genotype; the differences were
calculated for each mouse and expressed as percentage of baseline by
using the following formula: [(L9M − LB) / LB] × 100. For the
statistical comparison between two groups (a–c), we employed paired t
tests, whereas for the comparison of three groups (d), we performed one-
way ANOVA followed byNewman-Keuls post hoc test. ***P < 0.001 vs.
wt; **P < 0.01 vs. wt; *P < 0.05 vs. wt; +P < 0.05 vs. casp1−/−
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casp1−/− and wt mice displayed nonsignificant differences in
their locomotor activity and motor coordination performance.
It is noteworthy that casp1−/−mice showed a lower number of
activated microglia that did not result in a higher number of
TH neurons, and/or better motor capabilities than wt mice.
Identifying key players driving the neuroinflammatory cas-
cade during PD could aid in the development of novel thera-
peutic strategies to counter some of its deleterious effects.
Successful novel interventions in preclinical studies continue
showing the po ten t i a l bene f i t o f t a rge t ing the
neuroinflammatory cascade to protect dopaminergic neurode-
generation in rodent models of PD [45, 46]. Clinical and post-
mortem studies have also demonstrated the occurrence of
CNS inflammation in living and deceased subjects with PD,
respectively [34, 47]. Furthermore, epidemiological data sug-
gested that the chronic use of anti-inflammatory drugs de-
creases the risk of developing PD [48]. Consequently,
targeting neuroinflammatory mediators in patients with PD
has been proposed as a potential clinical approach to halting
dopaminergic neurodegeneration [49, 50]. Our current results
in IL-1ra−/− mice (the strain displaying activation of the IL-1
system) and other studies previously reported in rodents sup-
port the concept that IL-1 is involved in microglia activation
leading to increased dopaminergic neurodegeneration
[15–17]. Thus, therapeutic strategies antagonizing IL-1 might
yield a potential benefit in treating patients with PD.
There are some potential limitations to our study that
should be acknowledged. The behavioral data compared
Fig. 3 Immunostaining of TH-
positive neurons and CD68-
positive microglia cells. Frozen
sections of mouse brains were
stained with anti-TH and anti-
CD68 antibody at 15 months.
Positive TH immunostaining of a
wt, c casp1−/−, and e IL-1ra−/−,
and positive CD68-
immunostaining of b wt, d
casp1−/−, and f IL-1ra−/− mice
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motor skills assessments obtained at baseline and 9 months,
whereas the histological studies were performed at 15 months.
The elapsed time between these experiments could have fa-
vored the progression of dopaminergic neurodegeneration. In
female mice receiving five monthly LPS injections, the loss of
dopamine neurons reached 37 % 9 months after the first LPS
injection and progressed to 55 % after 20 months of the first
endotoxin administration [21]. In our studies, dopaminergic
neurodegeneration may also have progressed between 9 and
15 months. Since some of the mice of the current study also
served as controls for another project that required ascertain-
ing insulin resistance by performing intraperitoneal glucose
tolerance test (GTT), we carried out the histological studies
at a later time-point to reduce the number of mice employed in
our experiments. The ascertaining of GTT involved an acute
exposure to a moderate level of stress. We cannot rule out that
the GTT studies could have also affected the histological ex-
periments. In order to minimize this putative confounding
effect, mice were euthanized shortly after the test was done
(7–10 days later). Mice deficient in IL-1ra bred in the BALB/c
background spontaneously developed polyarthropathy, which
closely resembles rheumatoid arthritis in humans [51]. The IL-
1ra−/− mice employed here were bred in the C57Bl6 back-
ground, which do not show similar signs of chronic inflam-
mation [51]. However, the IL-1ra−/− mice used in our studies
are approximately 20 % smaller than wt mice, which could
have influenced some of the data reported here. Also, it was
recently shown that casp1-targeted mice carry a 129 ES cell-
derived mutation in the casp11 gene, which appeared to be
involved, at least in part, in their resilience to LPS-induced
lethality [52]. Thus, we cannot rule out that some of the results
observed in casp1−/− are also influenced by the lack of casp11
activity.
Future studies should be carried out to address the putative
contribution of brain overactivation of the IL system. One
possibility to address this issue would be to design experi-
ments employing mice with brain-specific deficiency of IL-
1ra and perform similar measurements for histological and
behavioral assessments. Data from those experiments could
be compared with the results reported presently.
Collectively, our data suggest that long-term exposure to
increased IL-1β/IL-1α could evoke parkinsonism-related out-
comes such as impairment in motor skills, a higher number of
activated microglia, and reduced number of TH-neurons as
described in IL-1ra−/− mice. Since all of these changes oc-
curred during normal aging of the IL-1ra−/− mice in the ab-
sence of brain inflammatory insults that are frequently caused
by intracerebral injections in animal models of PD, we provide
novel evidence suggesting that chronic activation of the IL-1
system can elicit parkinsonism per se. In contrast, long-term
exposure to reduced levels of IL-1β/IL-1α as observed in
casp1−/− mice failed to alter long-term motor skills despite
the fact that these mice showed a lower number of activated
microglia when compared to wt mice. The elucidation of the
inflammatory mediators that play key roles in PD is crucial to
develop new therapeutic strategies to overcome this deleteri-
ous condition.
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Fig. 5 Microglia cell count. Eight evenly spaced frozen sections that
encompassed the entire SN were stained with anti-CD68, a marker for
activated microglia. Total count of CD68-positive cells was counted uni-
laterally in the region of SN of wt (n = 11), casp1−/− (n = 6), and IL-1ra−/−
(n = 6) mice and analyzed by one-way ANOVA followed by Newman-
Keuls post hoc test. Error bars represent standard errors. **P < 0.01 vs.






















Fig. 4 Dopamine neurons cell count. Mice brains were stained with anti-
TH at 15months. The total number of TH-positive cells from eight evenly
spaced frozen sections that encompassed the entire SN of wt (n = 11),
casp1−/− (n = 7), and IL-1ra−/− (n = 7) mice was evaluated from the uni-
lateral side of SNpc. Data were analyzed by one-wayANOVA (Newman-
Keuls post hoc test). Error bars represent standard errors. **P < 0.01 vs.
wt; ++P < 0.01 vs. casp1−/−
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